Sanofi Reports P-II Study Results of Frexalimab for the Treatment of Relapsing Multiple Sclerosis
- The P-II trial results presented at CMSC 2023 evaluating high or low doses of frexalimab vs PBO in a ratio (4:4:1:1) in 129 patients for 12wks. Patients receiving PBO shifted to frexalimab after 12wk. & entered in an ongoing open-label part B
- The trial met its 1EPs & showed that high & low-dose frexalimab patients achieved a reduction in no. of new GdE T1-lesions (89% & 79%) @12wk. & in new or enlarging T2-lesions & total GdE T1-lesions, patients were free of new GdE T1-lesions in high-dose (96%) @24wk. along with reduced disease activity
- Early effects on MSIS-29 physical impact score (PROs) & plasma NfL level will also report, 97% completed part A & continued to the open-label part B. The company also plans to initiate pivotal trials in MS in early 2024
Ref: Sanofi | Image: Sanofi
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.